Aileron Therapeutics, Inc. (ALRN, Financial), a clinical-stage biopharmaceutical company, experienced a significant stock price increase of 5.27%, reaching $2.70 per share with a trading volume of 25,275 shares. The stock's turnover rate was 0.12%, and it showed a price fluctuation of 5.30%.
Recent financial reports indicate that Aileron Therapeutics recorded no revenue, a net loss of $5.85 million, and an earnings per share (EPS) of -$0.27. The company's gross profit stood at $0.00, resulting in a price-to-earnings (P/E) ratio of -0.93. Despite these figures, all participating analysts have given a "buy" rating, with no "hold" or "sell" recommendations.
Within the biotechnology sector, where Aileron operates, there was an overall increase of 0.68%. Other notable stocks in the sector included Neurosense Therapeutics Ltd, Protagenic Therapeutics Inc, and Cyclerion Therapeutics, Inc., which showed significant gains. Cyclerion Therapeutics, Inc., Outlook Therapeutics, Inc., and Tc Biopharm (Holdings) Plc were particularly active, with turnover rates of 1037.39%, 253.90%, and 66.98% respectively. Stocks with large price swings included Neurosense Therapeutics Ltd, Silexion Therapeutics Corp, and Protagenic Therapeutics Inc.
Aileron Therapeutics is focused on developing innovative therapies for cancer and other diseases. Its lead candidate, ALRN-6924, aims to protect healthy cells in cancer patients with p53 mutations from chemotherapy side effects. The company is also advancing two other clinical-stage candidates, LTI-03 and LTI-01, along with several preclinical products targeting fibrotic conditions.
